MoonLake Immunotherapeutics (MLTX)
NASDAQ (CM) NASDAQ (CM) Primary Summary
MoonLake: 'Buy' Sonelokimab BLA Submission HS September And Label Expansion
MoonLake Immunotherapeutics maintains a Buy rating, supported by positive FDA interactions and strong long-term data for sonelokimab in hidradenitis suppurativa [HS]. MLTX expects to submit a BLA for sonelokimab in HS by end of September 2026, targeting both adults and adolescents, with possible acceptance for review by November 2026. 52-week VELA data show 67.2% HiSCR75 response, positioning sonelokimab as a potential best-in-class therapy and supporting a broad label proposal thanks to VELA-TEEN adolescent study.
MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript
MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript
Avoro Capital Advisors LLC Cuts Stock Position in MoonLake Immunotherapeutics $MLTX
Avoro Capital Advisors LLC lessened its holdings in shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) by 51.8% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,000,000 shares of the company's stock after selling 2,150,000 shares during the period. MoonLake
MoonLake Immunotherapeutics Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 1 | $13 | $19.49 | $6.49 | 49.92% |
 Point72 Asset Management LP Point72 Asset Management LP | 1.37M | $21.62M | $26.62M | $4.99M | 23.09% |
 Didric Cederholm Lion Point Capital LP | 67,500 | $483,975 | $1.32M | $833,422.5 | 172.2% |
| NM Nir Messafi Deep Track Capita LLP | 6.41M | $94.29M | $124.52M | $30.23M | 32.06% |
 Joseph Castro Nuveen LLC | 33,417 | $1.52M | $650,294.82 | -$867,962.88 | -57.17% |
MoonLake Immunotherapeutics (MLTX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has MoonLake Immunotherapeutics ever had a stock split?
MoonLake Immunotherapeutics Profile
| Biotechnology Industry | Healthcare Sector | Jorge Santos da Silva CEO | NASDAQ (CM) Exchange | 61559X104 CUSIP |
| CH Country | 130 Employees | - Last Dividend | - Last Split | 20 Oct 2020 IPO Date |
Overview
MoonLake Immunotherapeutics is a pioneering clinical-stage biopharmaceutical entity, rooted in the mission to revolutionize therapeutic interventions for inflammation-related diseases. Established in 2021 and strategically based in Zug, Switzerland, this vanguard organization dedicates its efforts to the meticulous development of cutting-edge therapies. Through its innovative approach, MoonLake Immunotherapeutics is steadfast in its commitment to addressing the unmet medical needs of patients globally, harnessing the latest advancements in biotechnology to foster health and well-being.
Products and Services
- Sonelokimab
A forefront in MoonLake Immunotherapeutics’ portfolio, Sonelokimab stands as a novel investigational Nanobody aimed at the treatment of various inflammatory diseases. This groundbreaking therapy exemplifies the company's innovative edge in leveraging nanobody technology to potentially offer a new paradigm in the treatment of conditions characterized by inflammation.
- Hidradenitis Suppurativa Treatment
In its arsenal of solutions, MoonLake Immunotherapeutics is developing targeted treatments for hidradenitis suppurativa, a chronic skin condition that causes small, painful lumps under the skin. The company's focused research on this condition reflects its dedication to tackling complex diseases with significant patient impact.
- Psoriatic Arthritis and Axial Spondyloarthritis Management
Addressing the spectrum of manifestations in psoriatic arthritis and axial spondyloarthritis, MoonLake Immunotherapeutics is at the forefront of conceptualizing therapies that aim to alleviate the symptomatic burden of these debilitating conditions. By targeting the underlying inflammatory processes, the company endeavors to improve quality of life for affected individuals.
- Psoriasis Therapy
With a keen focus on dermatological conditions, MoonLake Immunotherapeutics also directs its research resources towards developing therapeutic options for psoriasis. Recognizing the diverse needs of psoriasis patients, the company's approach encapsulates a deep understanding of the disease pathology, aiming to deliver innovative and efficacious treatments.
